Semaglutide Changes Liver Enzymes and Cardiometabolic Markers in Obesity
Semaglutide treatment improved liver enzyme levels and cardiometabolic markers in obese individuals, demonstrating hepatic and metabolic benefits during weight loss.
Quick Facts
What This Study Found
Semaglutide treatment improved liver enzyme levels and cardiometabolic markers in obese individuals, demonstrating hepatic and metabolic benefits during weight loss.
Key Numbers
Data from December 2020 through November 2024 tracking liver enzymes and cardiometabolic markers in semaglutide-treated patients with obesity and MASH.
How They Did This
Study design and methodology detailed in the full publication.
Why This Research Matters
These findings have significant implications for peptide-based therapeutic development and clinical practice.
The Bigger Picture
This study contributes to the expanding understanding of how peptide-based therapeutics can be applied across medical specialties.
What This Study Doesn't Tell Us
Study-specific limitations discussed in the full publication. Results should be interpreted within the context of study design.
Questions This Raises
- ?What are the long-term implications?
- ?How do these results compare to existing evidence?
- ?What further research is needed?
Trust & Context
- Key Stat:
- Key finding Semaglutide treatment improved liver enzyme levels and cardiometabolic markers in obese individuals,
- Evidence Grade:
- Evidence assessment based on study design detailed in publication.
- Study Age:
- Published in 2025. Current peptide therapeutic research.
- Original Title:
- Changes in liver enzymes and cardiometabolic markers in individuals with obesity and metabolic-dysfunction-associated steatohepatitis treated with semaglutide.
- Published In:
- Current medical research and opinion, 41(11), 2089-2102 (2025)
- Authors:
- Albarmawi, Husam, Dabbous, Firas(2), Aly, Abdalla, Yousif, Alia, Huse, Samuel, Jara, Maximilian, Quintero, Andres, Lawitz, Eric
- Database ID:
- RPEP-09845
Evidence Hierarchy
Frequently Asked Questions
What does this study mean for patients?
Semaglutide treatment improved liver enzyme levels and cardiometabolic markers in obese individuals, demonstrating hepatic and metabolic benefits during weight loss.
How reliable are these findings?
Evidence strength depends on study design. Consult the full publication and your healthcare provider for personalized guidance.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09845APA
Albarmawi, Husam; Dabbous, Firas; Aly, Abdalla; Yousif, Alia; Huse, Samuel; Jara, Maximilian; Quintero, Andres; Lawitz, Eric. (2025). Changes in liver enzymes and cardiometabolic markers in individuals with obesity and metabolic-dysfunction-associated steatohepatitis treated with semaglutide.. Current medical research and opinion, 41(11), 2089-2102. https://doi.org/10.1080/03007995.2025.2596430
MLA
Albarmawi, Husam, et al. "Changes in liver enzymes and cardiometabolic markers in individuals with obesity and metabolic-dysfunction-associated steatohepatitis treated with semaglutide.." Current medical research and opinion, 2025. https://doi.org/10.1080/03007995.2025.2596430
RethinkPeptides
RethinkPeptides Research Database. "Changes in liver enzymes and cardiometabolic markers in indi..." RPEP-09845. Retrieved from https://rethinkpeptides.com/research/albarmawi-2025-changes-in-liver-enzymes
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.